Abivax Share Offering Reaches $920 Million After Option Exercise

By EC Assets · Published 2 July 2026

Biotechnology company Abivax has announced the full exercise of an underwriters' option to purchase additional American Depositary Shares (ADSs). This exercise increased the gross proceeds of a recent offering to $920 million. The company's shares experienced a jump following the news. The offering’s gross proceeds of $920 million are equivalent to €807 million. The offering includes the sale of 960,000 additional ADSs due to the exercised option. The net proceeds from this offering are designated for obefazimod and research and development (R&D) activities. Earlier, Abivax priced an upsized $800 million ADS offering at $125 per share. Underwriters had been granted an option to buy up to 960,000 additional ADSs, representing 15% of the deal. The full exercise of this option elevated total proceeds to approximately $920 million. The fundraising has contributed to a near $11 billion valuation for Abivax. The capital raised could alleviate pressure for a near-term acquisition. This article is intended for informational purposes only. It does not constitute investment advice.